Inspire Medical Systems (NYSE:INSP) Receives Market Perform Rating from Oppenheimer

Inspire Medical Systems (NYSE:INSP)‘s stock had its “market perform” rating reiterated by investment analysts at Oppenheimer in a research note issued on Thursday,Benzinga reports.

A number of other equities research analysts have also recently commented on the stock. Mizuho decreased their target price on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Tuesday. Jefferies Financial Group cut their price target on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating on the stock in a research note on Thursday, February 12th. JPMorgan Chase & Co. cut their price target on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research note on Tuesday. Morgan Stanley set a $60.00 price target on shares of Inspire Medical Systems in a research note on Wednesday, February 18th. Finally, Royal Bank Of Canada cut their price objective on shares of Inspire Medical Systems from $56.00 to $45.00 and set a “sector perform” rating on the stock in a research note on Tuesday. Four investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Inspire Medical Systems currently has an average rating of “Hold” and an average price target of $85.00.

Inspire Medical Systems Trading Up 1.7%

Shares of INSP traded up $0.79 during trading hours on Thursday, reaching $46.49. 1,038,348 shares of the stock traded hands, compared to its average volume of 1,225,000. The company has a market cap of $1.34 billion, a P/E ratio of 10.39, a price-to-earnings-growth ratio of 5.40 and a beta of 0.83. The company’s 50-day moving average price is $56.26 and its two-hundred day moving average price is $79.20. Inspire Medical Systems has a 52-week low of $44.41 and a 52-week high of $161.88.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.28) by $0.38. The company had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The firm’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, research analysts forecast that Inspire Medical Systems will post 0.84 EPS for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INSP. Wellington Management Group LLP purchased a new position in Inspire Medical Systems during the fourth quarter valued at $203,929,000. M&T Bank Corp purchased a new position in Inspire Medical Systems during the fourth quarter valued at $85,871,000. Deerfield Management Company L.P. lifted its stake in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares in the last quarter. Morgan Stanley lifted its stake in shares of Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after buying an additional 809,121 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. purchased a new position in shares of Inspire Medical Systems in the fourth quarter worth about $61,619,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.